Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris - 07/09/11
Abstract |
Background: Narrow-band UVB (NB-UVB) is a new phototherapy option for psoriasis. Action spectrum studies previously done with different UVB wavelengths suggest that suberythemogenic doses of NB-UVB could be highly effective in treating psoriasis vulgaris. Even so, no comparative studies with suberythemogenic doses of NB versus conventional UVB have been performed previously. Objective: Our purpose was to compare conventional broad-band UVB (BB-UVB) with NB-UVB at suberythemogenic doses for the treatment of psoriasis vulgaris. Methods: Eleven patients were treated using a split-body approach for 6 weeks on a three-times-a-week basis. Outcomes were evaluated by means of Psoriasis Severity Index scores and quantitative histologic measures. Results: We were able to induce clinical clearing in 81.8% of patients after NB-UVB, but in only 9.1% of patients after BB-UVB (P < .01). Biopsy specimens obtained at the end of treatment revealed that keratin 16 staining was absent in 75% of patients on the NB side compared with none on the BB side, suggesting a reversal of regenerative epidermal hyperplasia by NB-UVB. Conclusion: NB-UVB is superior to UVB-BB in reversing psoriasis at suberythemogenic doses when given three times per week. This schedule was well tolerated by all patients.(J Am Acad Dermatol 1999;40:893-900.)
Le texte complet de cet article est disponible en PDF.Plan
Supported in part by a General Clinical Research Center Grant (M01-RR00102) from the National Center for Research Resources at the National Institutes of Health (NIH); by NIH grant AI39214; by grants or gifts from The Carl J. Herzog Foundation, the American Skin Association, The Carson Family Charitable Trust, Dr. James Murphy, and the Langeloth Foundation. Dr Walters is supported as a Rockefeller University Clinical Scholar; Drs Burack and Coven were Rockefeller University Clinical Scholars from May 1996 through June 1997 and March 1997 through June 1998, respectively. |
|
Reprint requests: James G. Krueger, MD, PhD, Laboratory Head, Laboratory for Investigative Dermatology, The Rockefeller University, Box 178, 1230 York Ave, New York, NY 10021-6399. E-mail: kruegej@rockvax.rockefeller.edu. |
|
0190-9622/99/$8.00 + 0 16/1/97822 |
Vol 40 - N° 6
P. 893-900 - juin 1999 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?